The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Please sign up for SocialPicks site access - it's free!

 Dynavax Technologies Corp.  (DVAX) Trade Now »     Rate DVAX  -  Discuss DVAX  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
87.5%
Top:
0.0%
Rate DVAX:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

DVAX: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

From the Blogosphere

DVAX Completes Hep-B Enrollment – Analyst Blog
Logo1
38%

Recently, Dynavax Technologies Corp. (DVAX) announced the completion of enrollment for the first of three cohorts of patients receiving DV-601 hepatitis B (HBV) therapy in an open-label, dose-escalating early-stage study. The second cohort has been opened for enrollment. All commercial rights to this product are with Dynavax.

In the study conducted in Europe, up to 30 patients are to be administered with 6 injections of DV-601 over a period of three months. The study will evaluate the safety and tolerability of DV-601. The company expects to report top-line data from this study in the second...
By  StraightStocks   (-6.57%  risk: moderate)  11/19/09 Comment


Dynavax with new HEPLISAV Data (NASDAQ:DVAX)
Logo1
38%
In one of the most surprising news today, Dynavax Technologies Corporation (NASDAQ:DVAX) has announced that the first clinical data of their HEPLISAV has shown increase in the protection rate for chronic kidney disease patients. The data ...
By  StraightStocks   (-6.57%  risk: moderate)  10/30/09 Comment


Unusual 11 Mid-Day Movers 10/22: UAUA, CHRW, EEV, CRI Higher; DVAX, CVH, KND, SNDK Lower
Dynavax (NASDAQ: DVAX) 78.1% LOWER; The FDA has advised Dynavax and Merck that the balance of risk versus potential benefit no longer favors continued clinical evaluation of HEPLISAV in healthy adults and children. The FDA has also advised the companies that there may be potential for an acceptable risk versus benefit profile for HEPLISAV in patients with renal failure, and requested additional information from the companies before considering further pursuit of clinical studies in those patients. Dynavax and Merck are evaluating the FDA's response in considering next steps. In the meantime...
By  Street Insider   (+9.67%  risk: moderate)  10/22/08 Comment


Morning Movers 10/22: Coventry Health (CVH) Sinks On Results, SanDisk (SNDK) Down After Offer Pulled; Apple (AAPL) Higher On EPS
<>StreetInsider.com Morning Movers:

ICO Global Communications Limited (NASDAQ: ICOG) 100% HIGHER; was awarded at least $371 million in its litigation with The Boeing Company (NYSE: BA) and Boeing Satellite Systems International.

Dynavax (NASDAQ: DVAX) 40% LOWER; The FDA has advised Dynavax and Merck that the balance of risk versus potential benefit no longer favors continued clinical evaluation of HEPLISAV in healthy adults and children. The FDA has also advised the companies that there may be potential for an acceptable risk versus benefit profile for HEPLISAV in patients with renal failure,...
By  Street Insider   (+9.67%  risk: moderate)  10/22/08 Comment


Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) Climb on Successful Phase 3 Trial and Second Quarter Financial Results
Logo1
38%

Dynavax Technologies Corporation (NASDAQ: DVAX), a developer of innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergy, cancer and chronic inflammatory diseases by utilizing versatile, proprietary approaches to alter immune system responses, recently announced the results form a Phase 3 clinical trial and the company’s second quarter financial results.

<>Shares of Dynavax Technologies climbed higher earlier this week after the company announced positive top line results from a Phase 3 clinical trial comparing HEPLISAVâ„¢, an investigation<><><>< /><><><><>< /><><>< /><>< /><>< />< />...
By  StraightStocks   (-6.57%  risk: moderate)  08/08/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
LEH Lehman Brothers Holdings Inc
F Ford Motor Company
INTC Intel Corp
AIG American International Group Inc.
BA The Boeing Company
SIRI Sirius Satellite Radio Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on DVAX

Visit streetinsider.com


Discussion Wall + Add  

Bulldozer1a
jay pollard   (+1.04%  risk: conservative)
my pick of the day - maybe maybe not???????????
+   0 replies


More Resources

Graphic_arrow1 About Dynavax Technologies Corp. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch